The COVID-19 crisis brought critical care medicine into the global spotlight and re-exposed systemic gaps in patient care. Four years after the initial surge of cases, the Max Harry Weil Institute for Critical Care Research and Innovation at the University of Michigan is asking the question: where do we go from here?
Read MoreA research team led by Weil Institute Associate Director Xudong (Sherman) Fan, PhD has received a $5.7 million grant from the NIH SCENT program to develop a portable sensor that uses body odor to detect over 20 acute and chronic, inflammatory, metabolic, respiratory, cardiovascular and skin diseases in both adults and children.
Read MoreThe U.S. Food and Drug Administration (FDA) has provided 510k clearance to market Michigan Medicine device spin-off company Fifth Eye, Inc.’s clinical support software, the AHI System™, to hospitals across the United States.
Read MoreThe Weil Institute Pre-Clinical Critical Care Laboratory (PC3L) is collaborating with medical device maker Abiomed, Inc. to examine the potential of using Abiomed Impella CP® left ventricular assist device as a resuscitative strategy for sudden cardiac arrest.
Read MoreThe U.S. Food and Drug Administration (FDA) has approved an Emergency Use Authorization (EUA) for the Aerosolve negative pressure procedure tent built in response to the COVID-19 pandemic.
Read MoreMichigan Medicine spin-off company, Fifth Eye, is launching their first product, the Analytic for Hemodynamic Instability (AHI).
Read MoreNew research shows a groundbreaking clinical tool, in development by Fifth Eye and Michigan Center for Integrative Research in Critical Care (MCIRCC), can reliably alert clinicians that a patient is at risk of developing hemodynamic instability — one of the most common causes of death for critically injured or ill patients — well before they deteriorate. This allows for earlier intervention before the patient progresses to cardiac arrest, organ injury, or other serious adverse events.
Read More
